Seleniso (XPOVIO/XPOVIO) user manual overview

Selinesol, trade name XPOVIO orXPOVIO, as the world's first oral XPO1 (nuclear export protein) inhibitor, has opened up a new treatment approach for patients with multiple myeloma and specific diffuse large B-cell lymphoma. To ensure therapeutic efficacy and patient safety, the following outlines the basic instructions for use of Seleniso.

1. Dosage guidance

1. For multiple myeloma: If used in combination with bortezomib and dexamethasone (SVd), take 100mg orally on the first day of each week; If used in combination with dexamethasone, take 80mg orally on the first and third days of each week

2. For relapsed/refractory diffuse large B-cell lymphoma: Take 60 mg orally every Monday and third day.

2. Instructions for taking medication

1. Take medicine regularly: Take medicine at a fixed time every week to maintain stable blood concentration.

2. Swallow whole: Take the entire tablet with a glass of water and avoid crushing or chewing.

3. Missed dose handling: If you miss a dose, take it at the next regular time to avoid double dose.

3. Important reminder

1. Drug interactions: Avoid using it at the same time with other drugs unless directed by a doctor to prevent interactions.

2. Adverse reaction monitoring:

Hematological toxicity: If anemia occurs, close monitoring is required and the dose should be adjusted or medication suspended in a timely manner.

Non-blood toxicity: such as nausea, vomiting, diarrhea, etc. Take appropriate measures according to symptoms.

Nervous system effects: May cause dizziness, confusion, avoid driving or handling heavy objects.

3. Special groups:

Pregnant and lactating women: A pregnancy test is required before treatment, and contraceptive measures should be taken during treatment and within one week after stopping the drug to avoid breastfeeding.

Children: Seleniso is not suitable for use in people under 18 years of age

4. Regular review

During the period of medication, you should undergo regular comprehensive examinations, including blood routine, liver and kidney function, etc., so that the treatment plan can be adjusted in a timely manner.

In summary, selinesol occupies an important position in the treatment of malignant tumors due to its unique targeted therapeutic properties. To ensure efficacy and safety, patients should strictly follow the above manual and conduct standardized treatment under the guidance of a doctor. Currently, Seleniso is sold at home and abroad. Patients should choose a suitable version of the drug based on their personal needs. At the same time, ensure that the purchase channel is formal and carefully identify the authenticity of the drug.